Detalhe da pesquisa
1.
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
Proc Natl Acad Sci U S A
; 110(9): 3501-6, 2013 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-23382202
2.
Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR.
Angew Chem Int Ed Engl
; 55(36): 10909-12, 2016 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27496389
3.
Covalent-Allosteric Kinase Inhibitors.
Angew Chem Int Ed Engl
; 54(35): 10313-6, 2015 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-26110718
4.
KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.
J Clin Oncol
; 42(12): 1439-1449, 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38408285
5.
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour.
J Pathol
; 227(2): 223-33, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22294416
6.
Plasma Sequencing for Patients with GIST-Limitations and Opportunities in an Academic Setting.
Cancers (Basel)
; 14(22)2022 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36428589
7.
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.
Cancer Discov
; 11(1): 108-125, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32972961
8.
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).
Clin Sarcoma Res
; 9: 3, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30867899
9.
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage Strategy.
Mol Cancer Ther
; 18(11): 1985-1996, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31308077
10.
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S.
Chem Sci
; 10(46): 10789-10801, 2019 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31857889
11.
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.
J Med Chem
; 60(6): 2361-2372, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28225269
12.
Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.
J Med Chem
; 60(21): 8801-8815, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28991465
13.
Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib.
Oncotarget
; 7(27): 41390-41403, 2016 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27167336
14.
Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.
PLoS One
; 10(3): e0120531, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25781619
15.
Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.
Oncoimmunology
; 2(6): e24452, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23894705
16.
DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
Cancer Res
; 73(12): 3661-70, 2013 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23576565
17.
p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
PLoS One
; 7(5): e37776, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22662219
18.
Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
Eur Urol
; 57(4): 679-87, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19560254
19.
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.
Cancer Res
; 70(1): 150-9, 2010 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20028860
20.
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.
Cancer Res
; 69(17): 6941-50, 2009 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19706776